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Abstract
Background: High resolution genome-wide copy number analysis, routinely used in clinical diagnosis for several years,
retrieves new and extremely rare copy number variations (CNVs) that provide novel candidate genes contributing to
disease etiology. The aim of this work was to identify novel genetic causes of neurodevelopmental disease, inferred
from CNVs detected by array comparative hybridization (aCGH), in a cohort of 325 Portuguese patients with intellectual
disability (ID).
Results: We have detected CNVs in 30.1% of the patients, of which 5.2% corresponded to novel likely pathogenic CNVs.
For these 11 rare CNVs (which encompass novel ID candidate genes), we identified those most likely to be relevant, and
established genotype-phenotype correlations based on detailed clinical assessment. In the case of duplications, we
performed expression analysis to assess the impact of the rearrangement. Interestingly, these novel candidate genes
belong to known ID-related pathways. Within the 8% of patients with CNVs in known pathogenic loci, the majority had
a clinical presentation fitting the phenotype(s) described in the literature, with a few interesting exceptions that are
discussed.
Conclusions: Identification of such rare CNVs (some of which reported for the first time in ID patients/families)
contributes to our understanding of the etiology of ID and for the ever-improving diagnosis of this group of patients.
Keywords: CNVs, Neurodevelopment, Genotype-phenotype correlation, CUL4B overexpression
Background
Intellectual disability (ID) is one of the most common
neurodevelopmental disorders (NDDs), affecting nearly
3% of the population worldwide. ID has a complex eti-
ology resulting from the combination of environmental
and genetic factors [1]. Relatively recent approaches to the
identification of copy number variations (CNVs), have
highlighted the relevance of rare de novo, and essentially
private mutations that contribute to a significant propor-
tion of the risk of NDDs, being presently an unavoidable
element of diagnosis in the field of Neuropsychiatry, Neu-
ropediatrics and Neurodevelopmental Pediatrics.
A substantial number of ID patients have CNVs resulting
from deletions or duplications [2, 3]. The frequency of de-
tection of chromosome abnormalities and/or genomic rear-
rangements in patients with NDDs by array comparative
genomic hybridization (aCGH) depends mainly on the
patient inclusion clinical criteria and on the microarray
design; nevertheless, detection rates are usually higher in
patients with ID/developmental delay (DD) that also
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: pmaciel@med.uminho.pt
†Fátima Lopes and Fátima Torres contributed equally to this work.
1Life and Health Sciences Research Institute (ICVS), School of Medicine,
University of Minho, 4710-057 Braga, Portugal
2ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
Full list of author information is available at the end of the article
Lopes et al. Orphanet Journal of Rare Diseases          (2019) 14:164 
https://doi.org/10.1186/s13023-019-1135-0
present malformations or dysmorphic features and more
severe cognitive impairment [2]. The characterization
of these CNVs in different patient cohorts as well as in
the general population is necessary to clarify their
clinical relevance and establish adequate genotype-
phenotype correlations [4].
We present the results obtained by studying 325
Portuguese patients with idiopathic ID using aCGH, in
whom we found known and new candidate pathogenic
CNVs. As expected, the great majority of the detected
CNVs were rare and restricted to one patient/family; never-
theless, the efforts towards their characterization represent
a step forward in order to clarify their clinical and molecu-
lar significance.
Results
Global data
From the 325 patients, 30.1% had at least one non-
polymorphic CNV detected by aCGH (Part 1 of Add-
itional file 1: Table S1): 8% had pathogenic CNVs, 5.2% had
likely pathogenic CNVs and 16.9% had genomic variants of
unknown significance (VOUS). The remaining 69.9%
patients had only known polymorphic CNVs.
Pathogenic CNVs
The pathogenic CNVs detected were mainly de novo
CNVs, including deletions at 1p36.23-p36.21, 2p13.1–13.3,
3q22.1-q23, 5p15.33-p15.32, 6q25.3, 7q11.23, 8p23.1, 11q2
4.2-q25, 12q24.21-q24.22, 16p11.2, 17q21.31, 22q11.21 and
22q13.3, as well as duplications at 1q21.1, 12q24.21, 9q3
4.13–34.3, 13q12.12-q34, 14q32.31-q32.33, 14q32.33, 15q1
1.2-q13.1, 16p13.11, 21q11.2-q22.11, Xp11.22 and Xq28
(see Table 1 for the list of all patients and findings). For
most of these CNVs there are reports in the literature
describing the phenotypic and genetic findings for similar
patients, therefore only some particular cases are described
in detail and discussed in Part 1 of Additional file 1,
namely: (a) the interstitial deletion at 1p36.23-p36.21 found
de novo in patient R1, of interest since interstitial deletions
in this region are rarely described in association with
NDDs; (b) the deletion at 3q22.1-q23 found de novo in
patient R3, which reinforces the association of deletions
affecting FOXL2 gene with blepharophimosis syndrome; (c)
7q11.23 deletions, detected in two non-related patients (C2
and R29), neither of whom presents the classical Williams-
Beuren syndrome phenotype; (d) the 22q13.3 deletion
found in patient C7, due to the incomplete overlap of the
patient’s phenotype with that previously described for
Phelan-McDermid syndrome; (e) the 9q34 duplications, de-
tected in two non-related patients (C19 and R14): patient
C19 has an intragenic EHMT1 duplication and a clinical
presentation that overlaps the core phenotype of Kleefstra
syndrome, commonly caused by deletions or point muta-
tions affecting the EHMT1 gene; patient R14 has three de
novo duplications at 9q34.13-q34.3 (affecting the whole
EHMT1 gene), at 14q32.31-q32.33 and at 14q32.33, illus-
trating the difficulty to ascertain the specific role of each
imbalance in complex rearrangements. We also included in
this category CNVs occurring in risk-associated loci.
Likely pathogenic CNVs
Likely pathogenic CNVs were detected in 5.2% of patients
in this study (Table 2; Figs. 1 and 2). They comprise candi-
date ID-causative loci located in 1q43-q44, 2q11.2-q12.2,
7q33, 10q26.3, 17p11.2 and 20q13.12-q13.13 (losses); 1p2
2.1-p21.3, 7q33, 9q33.2-q33.3, 9q34.3, Xq24 and Xq26.3
(gains) (Table 2). Patients with 1q43-q44, 7q33 and 10q
26.3 CNVs have been described elsewhere in detail [5–7];
the patient with a 9q34.3 gain is described together with
patient R14 in Part 1 of Additional file 1; therefore, we
focus next on the remaining candidate loci.
2q11.2-q12.2 deletion
Patient R16 is a 17 year old girl with syndromic ID, cere-
bral ventricular enlargement, dysmorphic features and hir-
sutism. She carries a de novo 4.5Mb deletion at 2q11.2-
q12.2 affecting 26 genes, of which MAP4K4, FHL2,
POU3F3 and CNOT11 have the highest haploinsufficiency
score in DECIPHERr [8]. POU Class 3 Homeobox 3
(POU3F3) was previously reported deleted in a boy with
ID and dysmorphic features (such as flat nose, prominent
Table 1 Clinical overview of RC patients for whom non-
polymorphic CNVs vs likely benign and polymorphic CNVs were
detected in the aCGH
Pathogenic + Likely pathogenic (n = 23) Polymorphic CNVs (n = 134)
Gender Gender
Males 15 (65%) Males 84 (63%)
Females 8 (35%) Females 50 (37%)
ID ID
Syndromic 19 (83%) Syndromic 74 (55%)
Non-syndromic 4 (17%) Non-syndromic 60 (45%)
Borderline 1 (4%) Borderline 8 (6%)
Mild 15 (65%) Mild 75 (56%)
Moderate 6 (26%) Moderate 30 (22%)
Severe 0 (0%) Severe 15 (11%)
Profound 1 (4%) Profound 6 (4%)
History History
Sporadic 11 (48%) Sporadic 54 (40%)
Family history of ID 15 (65%) Family history of ID 80 (60%)
Co-morbidities Co-morbidities
Congenital anomalies 11 (48%) Congenital anomalies 64 (48%)
Epilepsy 2 (9%) Epilepsy 19 (14%)
Microcephaly 4 (17%) Microcephaly 23 (17%)
Macrocephaly 1 (4%) Macrocephaly 13 (10%)
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ears, large eyebrows and low hairline) [9], similar to those
of our patient. This gene encodes a transcription factor
present in post-mitotic cells and plays a role in neurogen-
esis and the correct destination of migratory neurons in
the cerebral cortex in the mouse [10], thus standing out as
a good candidate for the DD/ID in the patient.
17p11.2 deletions
Patient C15 is a 10 year old boy referred for consultation
for DD, namely language and motor impairment, ataxia
and some dysmorphic features, including hypertelorism,
strabismus and low-set ears. It was not possible to re-
evaluate for IQ testing, but at the time of first evaluation
he had no formal cognitive deficit (according with the
GMDS score when he was 5 years old) and cerebral
magnetic resonance imaging (MRI) showed no alter-
ations. He has what appear to be two consecutive dele-
tions at 17p11.2: a 420.6Kb deletion, that encompasses 5
genes, and a 2.77Mb deletion that encompasses 36
genes. He has inherited them from his mother, who has
confirmed learning difficulties, although she has com-
pleted the 6th grade. These deletions partially overlap
the region involved in Smith-Magenis syndrome (SMS);
however, the phenotype of the patient and mother is not
similar to that of SMS, and the deletion does not affect
the retinoic acid induced 1 (RAI1) gene, thought to
cause most of the SMS core phenotype [11]. Among the
genes affected by patient C15’s deletions, there are sev-
eral others whose function could potentially contribute
for his phenotype (detailed in Part 1 of Additional file 1).
20q13.12-q13.13 deletions
Patient R20 is a 16 year old girl with mild ID (IQ = 56),
speech delay, MIC and facial dysmorphisms. Brain imaging
studies revealed no structural alterations. She also has astig-
matism and attention deficit hyperactivity disorder
(ADHD). She carries a de novo 5.5Mb deletion at 20q13
.12-q13.13 encompassing 123 genes. Among these, the
genes KCNB1, PIGT, CTSA, SLC2A10 and ARFGEF2 were
associated with human disease (detailed in Part 1 of Add-
itional file 1).
1p22.1p21.3 duplications
Patient C16 is a 7 year old girl with motor and speech
delay, with a global DQ of 56.3 (GMDS). She carries a
maternal 1p22.1p21.3 duplication of 6.461Mb that af-
fects 44 genes. Her mother has completed the 6th grade
although with 2 in-grade retentions and always showing
learning difficulties, especially in language skills. The girl
has a 10 year old brother suspected of having cognitive def-
icit: he was not evaluated yet, but he is attending the 2nd
grade and does not yet know how to read. There is also a
positive history of learning difficulties on the maternal
grandfather’s family side. The duplication affects several
genes (Fig. 2a), including the FAM69A gene, which en-
codes a member of the FAM69 family of cysteine-rich type
II transmembrane proteins. FAM69 proteins are thought
to play a fundamental role in the endoplasmic reticulum,
in addition to specialized roles in the vertebrate nervous
system, according to a brain-specific or brain-including ex-
pression pattern [12]. Consistently, several FAM69 genes
have been linked to neuropsychiatric disorders: C3ORF58
(DIA1) with autism [13]; CXORF36 (DIA1R) with X-linked
ID [14] and FAM69A with schizophrenia and bipolar dis-
ease [15]. Even though the contribution of the excess of
dosage for NDDS is still unknown, this gene can be consid-
ered a good candidate to explain the disease in the patient.
9q33.2-q33.3 triplication
Patient R21 is a 17 year old girl with mild ID (IQ = 53)
and familial history of ID. During the neonatal period
she presented seizures (flexion spasms and later general-
ized tonic-clonic), controlled with Phenobarbital, which
was discontinued at 23 months; EEG initially showed
lateral paroxystic activity, bilaterally, and a normal result
at 6 months; brain MRI was normal. Additionally, she
presented dysmorphic facial features (Fig. 2), a muscular
ventricular septal defect that closed spontaneously,
hypothyroidism, hypotonia, global DD, growth deceler-
ation (height and weight around the 3rd centile after 12
months) with normal head size, around the 75th centile,
delayed bone maturation (~ 3 years), growth hormone
deficiency and short neck. She carries a 3.6 Mb de novo
triplication at 9q33.2-q33.3 that affects 60 genes. Of
those, only the CRB2 gene is associated with a human
disease. Moreover, this triplication apparently disrupts
the FBXW2 gene that encodes for an F-box protein. F-
box proteins are one of the four subunits of ubiquitin
protein ligases, called SCFs. SCF ligases bring ubiquitin
conjugating enzymes to substrates that are specifically
recruited by the different F-box proteins. Components
of this complex, such as CUL4B, have been involved in
ID pathogenesis [16]. Also included in the CNV are the
LHX2 and LHX6 genes, both encoding transcription
factors described to play roles in brain development [17,
18]. Additionally, LHX2 was also described to be in-
volved in osteoclast differentiation and its overexpres-
sion inhibits skeletal muscle differentiation [19]. LHX6 is
also known to play a role in cranial and tooth develop-
ment [20], hence these genes could be of relevance to
the cranioskeletal phenotype of the patient.
Based on the location within the triplication region and
the expression levels described we selected the FBXW2,
NEK6 and PSMB7 genes (detailed in Part 1 of Additional
file 1) to study at the mRNA level in peripheral blood in
the patient. The three genes had an increased expression
when compared to controls (Fig. 2b). For NEK6 these find-
ings are in accordance with the fact it is included inside
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the triplicated region. Regarding FBXW2 and PSMB7, we
had hypothesized that their expression could be dimin-
ished since they are located at the breakpoints, which we
concluded not to be the case. To the best of our knowledge
no mutations in any of these three genes were reported in
human NDDs, making their involvement in our patient’s
symptomatology difficult to confirm at this stage.
Xq24 duplication
Patient R22 is a 14 year old boy with borderline IQ (IQ =
80) and a familial history of ID (two brothers and cous-
ins with ID), an apparently benign cardiac arrhythmia,
overweight (BMI 23.6 Kg/m2 P90), stereotypies and
ADHD. He carries a 0.3 Mb maternally inherited dupli-
cation at Xq24 affecting four genes (CUL4B, LAMP2,
C1GALT1C1, MCTS1), his mother being asymptomatic.
Both point mutations and large deletions in the CUL4B
gene are described as causative of X-linked ID and cere-
bral malformations [21, 22]. CUL4B is a scaffold protein
member of the cullin family that works in the formation
of protein complex that acts as an E3 ubiquitin ligase
catalyzing the polyubiquitination of protein substrates.
CUL4B was found to be responsible for TSC2 degrad-
ation in neocortical neurons positively regulating mTOR
activity in those cells [23]. Additionally, CUL4B also tar-
gets WDR5 for ubiquitylation leading to its degradation
in neurons nucleus, which causes impaired neurite out-
growth [24]. However, to our knowledge, there is only
one 47.2Mb duplication encompassing CUL4B (and
other genes) described in a patient with ID [25], the
present case being the first small, non-disruptive CUL4B
duplication described in a patient with ID. CUL4B is en-
tirely duplicated in the patient and its expression in per-
ipheral blood cells is increased, leading to us to believe
that the disorder in the patient is in fact driven by a dos-
age increase in CUL4B. The LAMP2 gene, located in the
duplication breakpoint and encoding a protein with roles
in autophagy/lysosomal function, does not present
altered expression in the patient, suggesting that it may
not be contributing to this phenotype (Fig. 2c).
Fig. 1 Facial appearance of patients and schematic representation of the deletions. a Patient R16 facies, with low set posteriorly rotated ears,
anteverted ears with simplified helix, temporal narrowing with prominent metopic suture, arched eyebrows, synophrys, bilateral epicanthal folds,
bulbous nasal tip, thin upper lip, open mouth with downturned corners, micrognathia; pedigree and deleted region of chromosome 2
(highlighted in red in the chromosome scheme (above) and in grey in the genes’ portion (below), adapted from DECIPHER). b Patient
R20 facies, with wide forehead, strabismus, high nasal bridge, wide base of nose, bulbous nasal tip, short and smooth philtrum, thin
upper lip with effaced cupid’s bow, prominent central incisors and micrognathia; pedigree and deleted region of chromosome 20. c
Patient C15: deleted region in chromosome 17
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Xq26.3 duplication
Patient C20 is a 17 year old boy referred to the consultation
due to general DD. He carries a 570.1Kb duplication at
Xq26.3 inherited from his mother, who has a suspicion of
some cognitive impairment but for whom no formal
intellectual assessment was possible. He has a global DQ of
57.1 (evaluated at the age of 10 years), scoring below the
average in all GMDS sub-scales, namely on language and
eye-hand co-ordination, and is described as a friendly boy.
He has speech delay, dolichocephaly and several
Fig. 2 Overview of some patients with likely pathogenic duplications. a Patient C16 - facial appearance: mildly dysmorphic, with high forehead
and frontal bossing, thick eyebrows and mildly anteverted nares; pedigree, schematic representation of the duplicated 1p region and expression
pattern for genes FAM69A, DPYD and TGFBR3. b Patient R21 - facial appearance: large forehead, sparse lateral eyebrows, epicanthal folds, large
nose, anteverted nares, long smooth philtrum, downturned corners of mouth and micrognathia; pedigree, schematic representation of the
triplicated 9q region and expression pattern for genes FBXW2, NEK6 and PSMB7. c Patient R22 - facial appearance: mildly dysmorphic with large
forehead and frontal central hair whorl; pedigree, schematic representation of the duplicated Xq region and expression pattern for CUL4B and
LAMP2 genes. d Patient C20 - facial appearance: mildly dysmorphic patient with thick eyebrows, wide palpebral fissures and thin upper lip;
pedigree and schematic representation of the duplicated Xq region. B2M and PPIB were used as housekeeping genes; * p < 0.05 (Student t-test)
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dysmorphisms, including micrognatia, syndactyly and clin-
odactyly. His younger sister (8 years old) also carries the du-
plication but has no ID and has a normal development for
her age which, this being an X-linked gene, is not incom-
patible with the causality of disease. The duplication en-
compasses the several genes (Fig. 2d) including the
ARHGEF6 gene. ARHGEF6 encodes for a protein that be-
longs to a family of cytoplasmic proteins which activate the
Rho proteins by exchanging bound GDP for GTP. These
Rho GTPases play a fundamental role in numerous cellular
processes linked to the organization of the cytoskeleton, cell
shape, and motility [26]. ARHGEF6 specifically has been
implicated in the regulation of spine morphogenesis and
loss of function (LoF) mutations have been found in pa-
tients with X-linked ID [27]. A 2.8Mb duplication in
Xq26.2-Xq26.3 has also been described in two brothers
with ID and the ARHGEF6, PHF6, HPRT1 and SLC9A6
genes have been identified as potential contributors to
those patients’ phenotype [28]. When compared to this
publication, we can see that our patient’s duplication is
smaller and affects only the ARHGEF6 gene; nevertheless,
the phenotypic similarities between our patient and those
described by Madrigal and colleagues (namely ID, dolicho-
cephaly and facial dysmorphisms) suggest a determinant
role for ARHGEF6 gene in phenotypes associated with
Xq26 microduplications [28]. Expression data in the per-
iphery for some of the genes involved in the duplication
didn’t retrieve results that we could interpret.
CNVs of unknown significance
In the VOUS group, we included CNVs which did not
encompass a known NDDs-related CNV region and for
which (i) pathogenicity was not sufficiently supported by
biological data, and/or (ii) similar copy number
changes were described in control databases, and/or (iii)
were inherited from a parent for whom the clinical pres-
entation was not known. For 50% of these cases, inherit-
ance from parents was not possible to determine due to
parental sample unavailability, thus reducing our ability
to interpret their clinical significance. A summary of the
VOUS identified in this study is presented in Part 1 of
Additional file 1: Table S2).
Discussion
This study of a cohort of ID patients in whom most com-
mon causes of disease had been excluded allowed us to
find a reliable cause of disease in 8% of patients and to
propose novel candidate ID loci in 5.2%. Making a stricter
analysis and considering only the variants associated (or
likely associated) with disease we can consider that this
yield is comparable with several other similar studies, in
which percentages ranging between 8.5 and 16% were
achieved [29–31]. The CNVs classified as pathogenic often
appear de novo and affect (in general) dozens of genes.
Some difficulties arose when classifying several of these
CNVs as, in some cases, although they occurred in known
syndrome regions not all the patients carrying them
presented the major clinical features established for that
particular syndrome. In fact, even these well-established
pathogenic CNVs can be associated with a broad and dis-
tinctive phenotypic presentation, as observed in patients
C2 and R29, both with WBS associated deletions but not
presenting the full-blown phenotype of this syndrome. In
this perspective, we believe that the main contributions of
this work are: (I) the reporting of new patients with CNVs
in regions associated with identified syndromes but with
different clinical presentations; (II) the reporting of novel
candidate ID-causative loci at 2q11.2-q12.2 (del), 7q33
(del and dup), 10q26.3 (del), 17p11.2 (del), 20q13.12-
q13.13 (del), 1p22.1-p21.3 (dup), 9q33.2-q33.3 (tri), 9q34.3
(dup), Xq24 (dup) and Xq26.3 (dup); (III) the study in
patients with copy number gains of the mRNA expression
in peripheral blood for genes located either inside the
duplicated/triplicated regions and/or at the breakpoints,
making it possible to determine if there is an actual effect
of gene dosage at the transcription level. Many of the
CNVs here detected by aCGH were rare and restricted to
one patient/family, which made their contribution to the
patient’s phenotype difficult to assess. Several of these
have been therefore classified as VOUS and their clinical
significance needs to be carefully addressed in future stud-
ies. Individually rare intermediate-size CNVs (frequency,
≤0.05%; ≥250 kb), and not necessarily assigned a priori as
pathogenic, appear to be collectively common in unse-
lected populations (10.5%), and have been associated with
ID and negatively with educational attainment [4]; being
so, even these should not be excluded as cause of disease
but rather re-assessed in the face of accumulating infor-
mation, in order to establish useful genotype-phenotype
correlations. Nevertheless, one cannot exclude the possi-
bility that some of these CNVs are unrelated to pathogen-
esis, namely in patients where no other genomic testing
(such as whole-exome or whole-genome sequencing) was
performed to rule out other causes, this being a potential
limitation of this work.
NDDs associated pathways: old and new genes
The likely pathogenic CNVs here proposed as novel candi-
date loci for ID encompass several genes that either were
already associated with NDDs (like CUL4B) or are now
proposed to have a role in ID and which can be grouped
according to their function in several cellular aspects:
Transcriptional factors/cell cycle regulators/DNA repair
proteins
Transcriptional regulation is an essential component of
the neuronal differentiation programs and of the response
to stimulation patterns underlying neuronal plasticity;
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genes involved in these pathways have been implicated in
well-known NDDs, as is the case of FOXL2 [32], BAZ1B
[33], and EBF3 [7]. This work revealed genes that appear
to be good candidate loci for ID; of those, POU3F3,
already described deleted in a patient with ID [9], stands
as a strong candidate.
Chromatin modifiers/chromatin remodeling proteins
An excess of mutation genes encoding proteins involved
in chromatin regulation have been described in NDDs
[34]. EHMT1 and ARID1B belong to this category and
are known to be associated with ID for many years. Here
we describe two more patients with duplications affect-
ing the EHMT1 gene, in one of which it was possible to
show EHMT1 overexpression. ARID5A encodes for a
protein belonging to the ARID family of proteins with
important roles in development, tissue-specific gene
expression and proliferation control [35].
Ubiquitin signaling
Ubiquitin-mediated degradation of proteins is a crucial
mechanism for cell maintenance and viability [36]. Several
genes belonging to this pathway are described to be associ-
ated with NDDs, as is the case of CUL4B [21], shown here
to be duplicated in two patients. UBE2C encodes a key
component of the ubiquitin proteasome system (UPS) that
participates in cell cycle progression and checkpoint control
[37]. The NEURL3 and CNOT4 genes also encode for
proteins with E3 ubiquitin-protein ligase activity; as for
FBXW2, it encodes for one of the four types of subunits of
SCF ubiquitin-protein ligases. Neither of these genes has
been linked, until now, with NDDs, but our findings
reinforce the idea that genes encoding for proteins belong-
ing to the UPS are possible new candidate genes for NDD
phenotypes.
Cytoskeleton regulation and organization, cell shape and
motility
Several NDDs are caused by mutations in genes regulat-
ing neuronal migration, which often encode for proteins
involved in the function of the cytoskeleton [38]. TSC1,
involved in microtubule-mediated protein transport due
to unregulated mTOR signaling [39], and ARHGEF6,
here described in different CNVs, have been previously
associated with NDDs [39, 40]. B9D1 has been con-
firmed as a novel Meckel syndrome gene [41].
Intracellular vesicular trafficking and exocytosis
In this work we report a patient with a deletion encom-
passing ARFGEF2, previously described associated with
epilepsy and ID (in the case of homozygous mutations)
[42, 43]. The collection of patients presented herein also
allowed the first description of EXOC6B gene
haploinsufficiency in association with DD/ID (reported
in detail in a dedicated publication) [44].
Signaling mediators/transducers/ receptor activity/
transmembrane proteins
Disruption of synaptogenesis has been associated with ID
and NDDs [45] and in this work we could identify CNVs in
several genes associated with this pathway. SEMA4C gene
encodes a transmembrane semaphorin which regulates
axonal guidance in the developing nervous system [46].
Syntaxins, such as Syntaxin 1A, encoded by STX1A gene,
are key molecules implicated in the docking of synaptic ves-
icles with the presynaptic plasma membrane [47]. Signaling
processes are essential for proper cellular function and usu-
ally implicate enzymes, transmembrane proteins and volt-
age ion-channels whose disruption may be associated with
disease [48]. Many of the genes described herein, including
CACNA1C, GPR45, TNFRSF13B, FAM69A, AKT3 and
CSE1L, are associated with these pathways, highlighting
once again the crucial contribution of proper cellular signal-
ing and synapse development and function for ID/DD.
Of notice, and although our attempts of establishing
genotype-phenotype correlations was mostly focused on
dosage impact of individual genes (e.g. haploinsufficiency/
overexpression), CNVs may also lead to disease through
other mechanisms, namely gene fusion generation [49] and
impact on genome architecture, for example Topological
Associated Domain disruption, with impact on the expres-
sion of genes located outside the affected regions [50].
Conclusion
The aCGH technology has for long been used in the
research and clinical contexts allowing the delineation of
many new microdeletion and microduplication syndromes.
In the last decade a decrease in the rate at which new
syndromes were described has been observed, most likely
because the most frequent/recurrent CNVs were described
in the early days of aCGH [51]. For the remaining and rarer
(often “private”) forms, it is still important, however, to
make an effort to share their clinical and genetic features as
well as the CNV data, to support future diagnosis and
establishment of genotype-phenotype correlations, as well
as the identification of novel candidate genes for disease, as
those advanced here.
Subjects and methods
Subjects
This work included the analysis of 325 ID patients (full
IQ (FIQ) below 70 and borderline FIQ 70–80) of Portu-
guese origin (36.9% females, 63.1% males), of which 188
(mostly trios) were included in a research cohort (RC)
and 137 were studied in the context of routine clinical
genetics diagnostics (clinical cohort, CC), all being refer-
enced as having NDDs (detailed description of inclusion
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criteria and clinical characterization provided in Part 1
of Additional file 1). For the RC we were able to obtain
DNA for all the parents as well as a more extensive clin-
ical description (see Table 3).
Methods
Genomic DNA was extracted from peripheral blood using
either the Citogene® DNA isolation kit (Citomed, Portugal)
manually or the QIAsymphony SP kit and apparatus.
aCGH was performed using the following platforms Agilent
180 K (GPL15397); KaryoArray®v3.0 (Agilent 8x60k); Agi-
lent Whole Genome 244 K (GPL10118); Affymetrix CytoS-
can HD (GPL1613) or CytoScan 750 K (GPL18637)
(detailed description provided in Additional file 1).
Data analysis
CNVs detected were classified using criteria adapted
from those previously described elsewhere [3, 52] as:
pathogenic, likely pathogenic, CNVs of unknown clinical
significance (VOUS) (detailed description in Part 2 of
Additional file 1). For simplification of terminology
throughout the text and in the tables, the term CNV is
used for pathogenic and likely pathogenic variants, as
well as VOUS. Polymorphic CNVs were not further
considered in our analysis, except where specifically in-
dicated (e.g. known risk loci, although relatively fre-
quent, were considered pathogenic). All alteration are
described in the tables as in the Decipher database (for
example 12q24.21-q24). For CNV confirmation we per-
formed qRT-PCR (7500-FAST Real Time PCR, Thermo
Fisher Scientific, Waltham, MA, USA), using SDC4 and
ZNF80 as reference genes (detailed description in Part 2
of Additional file 1; primers in Table S3). Total RNA
was isolated from leukocytes using the QIAsymphony
RNA Kit (QIAGEN GmbH, Germany), according to the
manufacturer’s protocol. First-strand cDNA synthesized
using SuperScript® III Reverse Transcriptase (RT)
(Thermo Fisher Scientific, Waltham, MA, USA). Expres-
sion analysis was performed by quantitative real-time re-
verse transcription PCR (qRT-PCR) using Power SYBR
Green® (Thermo Fisher Scientific, Waltham, MA, USA)
(detailed description in Part 2 of Additional file 1; genes
and primers listed in Table S4).
Additional file
Additional file 1: Figure S1. Facial appearance of some patients
carrying pathogenic variants. Figure S2. Clinical features of patients R14
and C19 and images of their CNVs. Table S1. Patients with altered aCGH
results (i.e. with CNVs classified as non-polymorphic). Table S2. List of
variants of unknown clinical significance (VOUS). Table S3. Primers used
for quantitative PCR confirmation. Table S4. Primers used for expression
studies. Table S5. OMIM entrance, haploinsufficiency score and constrain
metrics for the selected genes in patient R16. Table S6. OMIM entrance,
haploinsufficiency score and constrain metrics for the selected genes in
patient C15. Table S7. OMIM entrance, haploinsufficiency score and con-
strain metrics for the selected genes in patient R20. Table S8. OMIM en-
trance, haploinsufficiency score and constrain metrics for the selected
genes in patient C16. Table S9. OMIM entrance, haploinsufficiency score
and constrain metrics for the selected genes in patient R21. Table S10.
OMIM entrance, haploinsufficiency score and constrain metrics for the se-
lected genes in patient C19. Table S11. OMIM entrance, haploinsuffi-
ciency score and constrain metrics for the selected genes in patients R22
and R23. Table S12. OMIM entrance, haploinsufficiency score and con-
strain metrics for the selected genes in patient C20. (DOC 11550 kb)
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